Orforglipron

What It Is

Orforglipron (brand name Foundayo) is a once-daily oral small-molecule GLP-1 receptor agonist developed by Eli Lilly. Unlike injectable GLP-1 drugs and oral semaglutide, orforglipron is a non-peptide molecule that can be taken any time of day without food or water restrictions. It received FDA approval on April 1, 2026 — the fastest new molecular entity approval since 2002, completed in just 50 days under the Commissioner's National Priority Voucher program. Foundayo prescriptions began shipping April 6, 2026, via LillyDirect, with broad U.S. retail pharmacy and telehealth availability following shortly after. The Phase 3 ATTAIN program demonstrated dose-dependent weight loss of 7.5% to 11.2% at 72 weeks in adults with obesity without diabetes (ATTAIN-1), and 5.1% to 9.6% in adults with obesity and type 2 diabetes (ATTAIN-2). A population-adjusted indirect treatment comparison presented at Obesity Medicine Association 2026 found that oral Wegovy (semaglutide 25 mg) demonstrated significantly greater mean weight loss than orforglipron 36 mg based on OASIS 4 vs ATTAIN-1 data, though orforglipron's no-restriction dosing convenience remains a differentiator. Foundayo is included in the Medicare GLP-1 Bridge program launching July 1, 2026, available to eligible Part D beneficiaries for a $50 copayment. Orforglipron represents a significant advance in accessibility for GLP-1 therapy, removing the need for injections entirely. In a head-to-head comparison, orforglipron 36 mg lowered A1C by 2.2% compared with 1.4% for oral semaglutide 14 mg, and patients who received orforglipron 36 mg lost 19.7 pounds compared with 11.0 pounds with oral semaglutide 14 mg — demonstrating superiority over the first-generation oral GLP-1 in glycemic and weight endpoints. The ATTAIN-Maintain Phase 3 trial demonstrated that oral orforglipron can effectively preserve weight loss achieved with injectable GLP-1 therapies. In a 52-week study, patients who switched from injectable semaglutide (Wegovy) to orforglipron maintained their weight loss with an average difference of only 0.9 kg, while those switching from tirzepatide (Zepbound) maintained with a 5.0 kg average difference — establishing orforglipron as a viable oral maintenance option after injectable-initiated weight loss. In May 2026, Eli Lilly announced the third successful Phase 3 trial of orforglipron for obesity, triggering global regulatory submissions for the weight management indication this year. This trial broadens the evidence base across diverse patient populations. An NIH-funded study published in Nature (2026) revealed a new mechanism by which oral small-molecule GLP-1 drugs suppress hedonic feeding (eating for pleasure). Researchers at the University of Virginia found that small-molecule GLP-1 agonists penetrate deep into the brain to activate the central amygdala — a region associated with desire that was not previously known to be directly reachable by GLP-1 drugs. Once activated, the central amygdala reduces dopamine release into the brain's reward circuitry during pleasure-driven eating. This pathway is separate from previously described appetite-suppression mechanisms and may explain emerging observations that GLP-1 drugs reduce addictive behaviors beyond food, including substance use disorders. The competitive landscape for oral GLP-1 therapies intensified in May 2026 with the nationwide launch of Ozempic tablets (oral semaglutide) at prices starting from $149/month and aleniglipron's ACCESS II 44-week data showing 16.3% weight loss — the highest efficacy for any oral GLP-1 RA. Orforglipron's differentiation rests on its non-peptide small-molecule structure, once-daily dosing without food restrictions, and established Phase 3 dataset.

Regulatory Status

Why Researchers Study It

Orforglipron is significant as the first oral non-peptide GLP-1 agonist to reach market. Its small-molecule design solves key limitations of peptide-based GLP-1 drugs: it doesn't require injection, has no food or water timing restrictions, and is stable at room temperature. This opens GLP-1 therapy to patients who are needle-averse or have difficulty with dosing restrictions.

Proposed Mechanisms

• Selectively activates GLP-1 receptors in the hypothalamus to reduce appetite
• Slows gastric emptying to prolong satiety after meals
• Stimulates glucose-dependent insulin secretion from pancreatic beta cells
• Small-molecule design provides oral bioavailability without permeation enhancers
• Does not require fasting or water restrictions due to non-peptide structure

Evidence Snapshot

Commonly Discussed Benefits

Safety & Cautions

Comparisons

See how Orforglipron compares to related peptides:

Calculator Tools

Use our research tools to explore dosing and reconstitution data:

Citations

1. [1] FDA Approves Foundayo (orforglipron) — FDA Press Release, April 2026 PubMed
2. [2] Eli Lilly — Foundayo FDA Approval Announcement, April 2026 PubMed
3. [3] Orforglipron Phase 2 results — NEJM 2023 PubMed
4. [4] Wegovy pill vs orforglipron indirect comparison — Obesity Medicine Association 2026 PubMed
5. [5] ATTAIN-Maintain: Orforglipron maintains weight loss after injectable GLP-1 switch — Eli Lilly 2026 PubMed
6. [6] NIH — Oral small-molecule GLP-1 drugs penetrate deep into the brain to suppress cravings. Nature 2026 PubMed
7. [7] Eli Lilly — ACHIEVE-3: Orforglipron superiority vs oral semaglutide in T2D (Lancet 2026) PubMed
8. [8] Orforglipron, an oral small-molecule GLP-1 receptor agonist, for obesity with T2D (ATTAIN-2) — The Lancet 2026 PubMed

Related Peptides